Table 1.
Patient- and transplant characteristics
| Variable | Category | Study group N=161 N (%) |
Control Group N=1074 N (%) |
|---|---|---|---|
| Age | Median (range) | 52 (21–73) | 52 (18–76) |
| Sex | F | 68 (42) | 425 (40) |
| M | 93 (58) | 649 (60) | |
| Disease | AML/ALL/ABL/MDSCR | 70 (44) | 398 (37) |
| AML/ALL/ABL/MDS active disease | 45 (28) | 189 (18) | |
| NHL/HD/MM | 36 (22) | 397 (37) | |
| AA/CML/other | 10 (6) | 90 (8) | |
| Relation | Related | 44 (27) | 436 (41) |
| Unrelated | 117 (73) | 638 (59) | |
| Matched | HLA-matched | 97 (60) | 777 (72) |
| HLA-mismatched | 64 (40) | 297 (28) | |
| Stem cells | PBSC | 121 (75) | 890 (83) |
| BM | 12 (8) | 57 (5) | |
| CB | 28 (17) | 127 (12) | |
| TCD | Y | 71 (44) | 547 (51) |
| N | 90 (56) | 527 (49) | |
| Conditioning | Myeloablative | 115 (71) | 688 (64) |
| Non-myeloablative | 46 (29) | 386 (36) | |
| TBI/dose | No TBI | 99 (62) | 544 (51) |
| Low dose | 22 (14) | 256 (24) | |
| High dose | 40 (25) | 274 (26) |
AML = acute myelogenous leukemia, ALL = acute lymphocytic leukemia, MDS = myelodysplastic syndrome, ABL = acute biphenotypic leukemia, NHL = non-Hodgkin’s lymphoma, HD = Hodgkin’s disease, MM= multiple myeloma, AA = aplastic anemia, CML = chronic myelogenous leukemia, CR = complete remission, PBSC = peripheral blood stem cells, BM = bone marrow, CB= cord blood TCD = T cell depleted, TBI = total body irradiation